These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 17214578)

  • 21. Anti-interferon alpha treatment in SLE.
    Kirou KA; Gkrouzman E
    Clin Immunol; 2013 Sep; 148(3):303-12. PubMed ID: 23566912
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The importance of the type I interferon system in autoimmunity.
    Rönnblom L
    Clin Exp Rheumatol; 2016; 34(4 Suppl 98):21-4. PubMed ID: 27586799
    [TBL] [Abstract][Full Text] [Related]  

  • 23. B-cell-targeted therapy for systemic lupus erythematosus.
    Sabahi R; Anolik JH
    Drugs; 2006; 66(15):1933-48. PubMed ID: 17100405
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Interleukin-2 signaling pathway regulating molecules in systemic lupus erythematosus].
    Guo Q; Chen XY; Su Y
    Beijing Da Xue Xue Bao Yi Xue Ban; 2016 Dec; 48(6):1100-1104. PubMed ID: 27987522
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Targeting interferons in systemic lupus erythematosus: current and future prospects.
    Mathian A; Hie M; Cohen-Aubart F; Amoura Z
    Drugs; 2015 May; 75(8):835-46. PubMed ID: 25940912
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Higher activation of the interferon-gamma signaling pathway in systemic lupus erythematosus patients with a high type I IFN score: relation to disease activity.
    Liu M; Liu J; Hao S; Wu P; Zhang X; Xiao Y; Jiang G; Huang X
    Clin Rheumatol; 2018 Oct; 37(10):2675-2684. PubMed ID: 29774490
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Lupus-like disease and high interferon levels corresponding to trisomy of the type I interferon cluster on chromosome 9p.
    Zhuang H; Kosboth M; Lee P; Rice A; Driscoll DJ; Zori R; Narain S; Lyons R; Satoh M; Sobel E; Reeves WH
    Arthritis Rheum; 2006 May; 54(5):1573-9. PubMed ID: 16645992
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Enhanced Inflammasome Activity in Systemic Lupus Erythematosus Is Mediated via Type I Interferon-Induced Up-Regulation of Interferon Regulatory Factor 1.
    Liu J; Berthier CC; Kahlenberg JM
    Arthritis Rheumatol; 2017 Sep; 69(9):1840-1849. PubMed ID: 28564495
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Type I interferon-mediated autoimmune diseases: pathogenesis, diagnosis and targeted therapy.
    Psarras A; Emery P; Vital EM
    Rheumatology (Oxford); 2017 Oct; 56(10):1662-1675. PubMed ID: 28122959
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Targeting the interferon pathway with sifalimumab for the treatment of systemic lupus erythematosus.
    Greth W; Robbie GJ; Brohawn P; Hultquist M; Yao B
    Immunotherapy; 2017 Jan; 9(1):57-70. PubMed ID: 28000522
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Type I interferon and systemic lupus erythematosus.
    Elkon KB; Stone VV
    J Interferon Cytokine Res; 2011 Nov; 31(11):803-12. PubMed ID: 21859344
    [TBL] [Abstract][Full Text] [Related]  

  • 32. An etiopathogenic role for the type I IFN system in SLE.
    Rönnblom L; Alm GV
    Trends Immunol; 2001 Aug; 22(8):427-31. PubMed ID: 11473831
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Interferon α-targeted therapy.
    Hanaoka H; Takeuchi T
    Nihon Rinsho Meneki Gakkai Kaishi; 2013; 36(4):181-8. PubMed ID: 23994795
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Artesunate inhibits type I interferon-induced production of macrophage migration inhibitory factor in patients with systemic lupus erythematosus.
    Feng X; Chen W; Xiao L; Gu F; Huang J; Tsao BP; Sun L
    Lupus; 2017 Jan; 26(1):62-72. PubMed ID: 27230555
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Targeting Interferon Signalling in Systemic Lupus Erythematosus: Lessons Learned.
    Jones SA; Morand EF
    Drugs; 2024 Jun; 84(6):625-635. PubMed ID: 38807010
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Interferons in Systemic Lupus Erythematosus.
    Sirobhushanam S; Lazar S; Kahlenberg JM
    Rheum Dis Clin North Am; 2021 Aug; 47(3):297-315. PubMed ID: 34215365
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Targeting of type I interferon in systemic autoimmune diseases.
    Crow MK; Olferiev M; Kirou KA
    Transl Res; 2015 Feb; 165(2):296-305. PubMed ID: 25468480
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The important roles of type I interferon and interferon-inducible genes in systemic lupus erythematosus.
    Luo S; Wang Y; Zhao M; Lu Q
    Int Immunopharmacol; 2016 Nov; 40():542-549. PubMed ID: 27769023
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Links between type I interferons and the genetic basis of disease in mouse lupus.
    Jørgensen TN; Gubbels MR; Kotzin BL
    Autoimmunity; 2003 Dec; 36(8):491-502. PubMed ID: 14984026
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Safety profile and clinical activity of sifalimumab, a fully human anti-interferon α monoclonal antibody, in systemic lupus erythematosus: a phase I, multicentre, double-blind randomised study.
    Merrill JT; Wallace DJ; Petri M; Kirou KA; Yao Y; White WI; Robbie G; Levin R; Berney SM; Chindalore V; Olsen N; Richman L; Le C; Jallal B; White B;
    Ann Rheum Dis; 2011 Nov; 70(11):1905-13. PubMed ID: 21798883
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.